1 Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest. 2012;142(2):448–56. doi:https://doi.org/10.1378/chest.11-1460.
2 Galiè N, Corris PA, Frost A, Girgis RE, Granton J, Jing ZC, et al. Updated treatment algo-rithm of pulmonary arterial hypertension. J Am Coll Cardiol. 2013;62(25, Suppl):D60–72. doi:https://doi.org/10.1016/j.jacc.2013.10.031.
3 Hoeper MM, Sosada M, Fabel H. Plasma coagulation profiles in patients with severe prima-ry pulmonary hypertension. Eur Respir J. 1998;12(6):1446–9. doi:https://doi.org/10.1183/09031936.98.12061446.
4 Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation. 1984;70(4):580–7. doi:https://doi.org/10.1161/01.CIR.70.4.580.
5 Galiè N, Humbert M, Vachiery J-L, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary artery hypertension. Eur Heart J. 2016;37:67–119.
6 Weitzenblum E, Sautegeau A, Ehrhart M, Mammosser M, Pelletier A. Long-term oxygen therapy can reverse the progression of pulmonary hypertension in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis. 1985;131(4):493–8.
7 Galiè N, Ussia G, Passarelli P, Parlangeli R, Branzi A, Magnani B. Role of pharmacologic tests in the treatment of primary pulmonary hypertension. Am J Cardiol. 1995;75(3):55A–62A. doi:https://doi.org/10.1016/S0002-9149(99)80384-1.
8 Sitbon O, Humbert M, Jaïs X, Ioos V, Hamid AM, Provencher S, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005;111(23):3105–11. doi:https://doi.org/10.1161/CIRCULATIONAHA.104.488486.
9 Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hyperten-sion: a randomised placebo-controlled study. Lancet. 2001;358(9288):1119–23. doi:https://doi.org/10.1016/S0140-6736(01)06250-X.
10 Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346(12):896–903. doi:https://doi.org/10.1056/NEJMoa012212.
11 Humbert M, Barst RJ, Robbins IM, Channick RN, Galiè N, Boonstra A, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J. 2004;24(3):353–9. doi:https://doi.org/10.1183/09031936.04.00028404.
12 Galiè N, Rubin Lj, Hoeper M, Jansa P, Al-Hiti H, Meyer G, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet. 2008;371(9630):2093–100. doi:https://doi.org/10.1016/S0140-6736(08)60919-8.
13 Galiè N, Beghetti M, Gatzoulis MA, Granton J, Berger RM, Lauer A, et al.; Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigators. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation. 2006;114(1):48–54. doi:https://doi.org/10.1161/CIRCULATIONAHA.106.630715.
14 Galiè N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, et al.; Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Mul-ticenter, Efficacy Studies (ARIES) Group. Ambrisentan for the Treatment of Pulmonary Arterial Hypertension: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2. Circulation. 2008;117:3010–9. doi:https://doi.org/10.1161/CIRCULATIONAHA.107.742510.
15 McGoon MD, Frost AE, Oudiz RJ, Badesch DB, Galie N, Olschewski H, et al. Ambris-entan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. Chest. 2009;135(1):122–9. doi:https://doi.org/10.1378/chest.08-1028.
16 Vachiéry J-L, Hoeper MM, Peacock AJ, Sitbon O, Cheli M, Church C, et al. Ambrisentan use for pulmonary arterial hypertension in a post-authorization drug registry: The VOLi-bris Tracking Study. J Heart Lung Transplant. 2017;36(4):399–406. doi:https://doi.org/10.1016/j.healun.2016.04.013.
17 Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani HA, et al.; SERAPHIN Investigators. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369(9):809–18. doi:https://doi.org/10.1056/NEJMoa1213917.
18 Galiè N, Jansa P, Pulido T, Channick RN, Delcroix M, Ghofrani HA, et al. SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension. Eur Heart J. 2017;38(15):1147–55. doi:https://doi.org/10.1093/eurheartj/ehx025.
19 Ghofrani HA, Voswinckel R, Reichenberger F, Olschewski H, Haredza P, Karadaş B, et al. Differences in hemodynamic and oxygenation responses to three different phos-phodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J Am Coll Cardiol. 2004;44(7):1488–96.
20 Tantini B, Manes A, Fiumana E, Pignatti C, Guarnieri C, Zannoli R, et al. Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells. Basic Res Cardiol. 2005;100(2):131–8. doi:https://doi.org/10.1007/s00395-004-0504-5.
21 Galiè N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, et al.; Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353(20):2148–57. doi:https://doi.org/10.1056/NEJMoa050010.
22 Simonneau G, Rubin LJ, Galiè N, Barst RJ, Fleming TR, Frost AE, et al.; PACES Study Group. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med. 2008;149(8):521–30. doi:https://doi.org/10.7326/0003-4819-149-8-200810210-00004.
23 Galiè N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, et al.; Pulmo-nary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group. Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009;119(22):2894–903. doi:https://doi.org/10.1161/CIRCULATIONAHA.108.839274. Correction in: Circula-tion. 2011;124(10):e279.
24 Jing ZC, Yu ZX, Shen JY, Wu BX, Xu KF, Zhu XY, et al.; Efficacy and Safety of Var-denafil in the Treatment of Pulmonary Arterial Hypertension (EVALUATION) Study Group. Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, place-bo-controlled study. Am J Respir Crit Care Med. 2011;183(12):1723–9. doi:https://doi.org/10.1164/rccm.201101-0093OC.
25 Ghofrani HA, Galiè N, Grimminger F, Grünig E, Humbert M, Jing ZC, et al.; PATENT-1 Study Group. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013;369(4):330–40. doi:https://doi.org/10.1056/NEJMoa1209655.
26 Wardle AJ, Seager MJ, Wardle R, Tulloh RMR, Gibbs JSR. Guanylate cyclase stimulators for pulmonary hypertension. Cochrane Database Syst Rev. 2016;(8):CD011205. doi:10.1002/14651858.CD011205.pub2.
27 Rubin LJ, Mendoza J, Hood M, McGoon M, Barst R, Williams WB, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med. 1990;112(7):485–91. doi:https://doi.org/10.7326/0003-4819-112-7-485.
28 Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al.; Primary Pulmo-nary Hypertension Study Group. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334(5):296–301. doi:https://doi.org/10.1056/NEJM199602013340504.
29 Olschewski H, Simonneau G, Galiè N, Higenbottam T, Naeije R, Rubin LJ, et al.; Aeroso-lized Iloprost Randomized Study Group. Inhaled iloprost for severe pulmonary hyperten-sion. N Engl J Med. 2002;347(5):322–9. doi:https://doi.org/10.1056/NEJMoa020204.
30 Kumar P, Thudium E, Laliberte K, Zaccardelli D, Nelsen A. A comprehensive review of teprostinil pharmacokinetics via four routes of administration. Clin Pharmacokinet. 2016;55(12):1495–505. doi:https://doi.org/10.1007/s40262-016-0409-0.
31 Tapson VF, Torres F, Kermeen F, Keogh AM, Allen RP, Frantz RP, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Chest. 2012;142(6):1383–90. doi:https://doi.org/10.1378/chest.11-2212.
32 Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, et al.; Treprostinil Study Group. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in pa-tients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002;165(6):800–4. doi:https://doi.org/10.1164/ajrccm.165.6.2106079.
33 McLaughlin VV, Benza RL, Rubin LJ, Channick RN, Voswinckel R, Tapson VF, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a ran-domized controlled clinical trial. J Am Coll Cardiol. 2010;55(18):1915–22. doi:https://doi.org/10.1016/j.jacc.2010.01.027.
34 Chakinala MM, Feldman JP, Rischard F, Mathier M, Broderick M, Leedom N, et al. Tran-sition from parenteral to oral treprostinil in pulmonary arterial hypertension. J Heart Lung Transplant. 2017;36(2):193–201. doi:https://doi.org/10.1016/j.healun.2016.06.019.
35 Ghosh RK, Ball S, Das A, Bandyopadhyay D, Mondal S, Saha D, et al. Selexipag in pul-monary artery hypertension: most updated evidence from recent preclinical and clinical studies. J Clin Pharmacol. 2017;57(5):547–57. doi:https://doi.org/10.1002/jcph.834.
36 Simonneau G, Torbicki A, Hoeper MM, Delcroix M, Karlócai K, Galiè N, et al. Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hy-pertension. Eur Respir J. 2012;40(4):874–80. doi:https://doi.org/10.1183/09031936.00137511.
37 Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galiè N, et al.; GRIPHON Investiga-tors. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373(26):2522–33. doi:https://doi.org/10.1056/NEJMoa1503184.
38 Hoeper MM, Barst RJ, Bourge RC, Feldman J, Frost AE, Galié N, et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IM-PRES study. Circulation. 2013;127(10):1128–38. doi:https://doi.org/10.1161/CIRCULATIONAHA.112.000765.
39 Kimura G, Kataoka M, Inami T, Fukuda K, Yoshino H, Satoh T. Sorafenib as a potential strategy for refractory pulmonary arterial hypertension. Pulm Pharmacol Ther. 2017;44:46–9. doi:https://doi.org/10.1016/j.pupt.2017.03.009.
40 Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, et al.; AM-BITION Investigators. Initial Use of ambrisentan plus tadalafil in pulmonary arterial hy-pertension. N Engl J Med. 2015;373(9):834–44. doi:https://doi.org/10.1056/NEJMoa1413687.
41 McLaughlin V, Channick RN, Ghofrani HA, Lemarié JC, Naeije R, Packer M, et al. Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. Eur Respir J. 2015;46(2):405–13. doi:https://doi.org/10.1183/13993003.02044-2014.
42 McLaughlin VV, Hoeper MM, Channick RN, Chin KM, Delcroix M, Gaine S, et al. Pul-monary artery hypertension-related morbidity is prognostic for mortality. J Am Coll Car-diol. 2018;71(7):752–63. doi:https://doi.org/10.1016/j.jacc.2017.12.010.